Gene expression profiles (GEP) and immunohistochemistry (IHC) from 31 KIT/PDGFRA-mutant GIST supported the presence of immune infiltrate, IFN-gamma-induced immune signature (EIIS) and the T-cell-inflamed signature (TIS), which suggests that GIST may benefit from immunotherapy along with tyrosine kinase inhibitors (Pantaleo et al., 2019). Here, PDGFRA is linked to gastrointestinal stromal tumor.